Pharmaco-economical analysis of Russian QUADRIGA Study data
Aim. To assess antihypretensive effect quality and duration for ACE inhibitor spirapril (Quadropril®; daily dose 6 mg) among arterial hypertension (AH) patients, in real-world out-patient clinical settings. Material and methods. The trial involved 11 Russian cities. This Russian multi-center, non-co...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250432543621120 |
|---|---|
| author | A. A. Kuprina Yu. B. Belousov |
| author_facet | A. A. Kuprina Yu. B. Belousov |
| author_sort | A. A. Kuprina |
| collection | DOAJ |
| description | Aim. To assess antihypretensive effect quality and duration for ACE inhibitor spirapril (Quadropril®; daily dose 6 mg) among arterial hypertension (AH) patients, in real-world out-patient clinical settings. Material and methods. The trial involved 11 Russian cities. This Russian multi-center, non-comparative, open study QUADRIGA (QUADRoprIl and AH) involved 235 AH patients with Stage I-II of blood pressure (BP) elevation; systolic BP (SBP) 140-179 mm Hg and/or diastolic BP (DBP) 90-109 mm Hg; age 25-75 years (mean age 51.1 years); <60 years – 74.8%, and 60 years – 25.2%; females – 54.5%; 17 patients with coronary heart disease, 32 patients with diabetes mellitus. Effectiveness criteria for Quadrorpil® antihypertensive action: normalization of SBP and/or DBP (<140/90 mm Hg); beneficial antihypertensive effect: DBP decrease 10 mm Hg; SBP decrease 20 mm Hg, in regard to baseline BP level. Results. During Quadropril® treatment, as monotherapy or in combination with a diuretic - hydrochlorthiazide was additionally administered to 122 patients (51.9%) - daily dose increase up to 25 mg was necessary in 78 participants; significant SBP and DBP reduction was observed. On average, SBP decreased from 159.8 to 132.8 mm Hg – by 25.7 mm Hg (16.1%), and DBP decreased from 98.7 to 83.3 mm Hg – by 15.1 mm Hg (15.3%). Target BP was achieved in 83.56% of the patients. Conclusion. According to Russian QADRIGA Study results, a new ACE inhibitor Quadropril® demonstrated good antihypertensive effect. Quadropril® in daily dose 6 mg, once per day, combined with hydrochlorthiazide 12.5-25 mg if needed, can be recommended for AH patients’ treatment. |
| format | Article |
| id | doaj-art-06f0d4e165324efebd1f47c4366b630d |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2006-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-06f0d4e165324efebd1f47c4366b630d2025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252006-04-01528993875Pharmaco-economical analysis of Russian QUADRIGA Study dataA. A. Kuprina0Yu. B. Belousov1Russian State Medical University. MoscowRussian State Medical University. MoscowAim. To assess antihypretensive effect quality and duration for ACE inhibitor spirapril (Quadropril®; daily dose 6 mg) among arterial hypertension (AH) patients, in real-world out-patient clinical settings. Material and methods. The trial involved 11 Russian cities. This Russian multi-center, non-comparative, open study QUADRIGA (QUADRoprIl and AH) involved 235 AH patients with Stage I-II of blood pressure (BP) elevation; systolic BP (SBP) 140-179 mm Hg and/or diastolic BP (DBP) 90-109 mm Hg; age 25-75 years (mean age 51.1 years); <60 years – 74.8%, and 60 years – 25.2%; females – 54.5%; 17 patients with coronary heart disease, 32 patients with diabetes mellitus. Effectiveness criteria for Quadrorpil® antihypertensive action: normalization of SBP and/or DBP (<140/90 mm Hg); beneficial antihypertensive effect: DBP decrease 10 mm Hg; SBP decrease 20 mm Hg, in regard to baseline BP level. Results. During Quadropril® treatment, as monotherapy or in combination with a diuretic - hydrochlorthiazide was additionally administered to 122 patients (51.9%) - daily dose increase up to 25 mg was necessary in 78 participants; significant SBP and DBP reduction was observed. On average, SBP decreased from 159.8 to 132.8 mm Hg – by 25.7 mm Hg (16.1%), and DBP decreased from 98.7 to 83.3 mm Hg – by 15.1 mm Hg (15.3%). Target BP was achieved in 83.56% of the patients. Conclusion. According to Russian QADRIGA Study results, a new ACE inhibitor Quadropril® demonstrated good antihypertensive effect. Quadropril® in daily dose 6 mg, once per day, combined with hydrochlorthiazide 12.5-25 mg if needed, can be recommended for AH patients’ treatment.https://cardiovascular.elpub.ru/jour/article/view/1163arterial hypertensionspiraprilpharmaco-economical analysis |
| spellingShingle | A. A. Kuprina Yu. B. Belousov Pharmaco-economical analysis of Russian QUADRIGA Study data Кардиоваскулярная терапия и профилактика arterial hypertension spirapril pharmaco-economical analysis |
| title | Pharmaco-economical analysis of Russian QUADRIGA Study data |
| title_full | Pharmaco-economical analysis of Russian QUADRIGA Study data |
| title_fullStr | Pharmaco-economical analysis of Russian QUADRIGA Study data |
| title_full_unstemmed | Pharmaco-economical analysis of Russian QUADRIGA Study data |
| title_short | Pharmaco-economical analysis of Russian QUADRIGA Study data |
| title_sort | pharmaco economical analysis of russian quadriga study data |
| topic | arterial hypertension spirapril pharmaco-economical analysis |
| url | https://cardiovascular.elpub.ru/jour/article/view/1163 |
| work_keys_str_mv | AT aakuprina pharmacoeconomicalanalysisofrussianquadrigastudydata AT yubbelousov pharmacoeconomicalanalysisofrussianquadrigastudydata |